Martina S.J. McDermott

Author

University of California, Los Angeles ORCID

Also Known As

M McDermott, M. McDermott, M.S. McDermott, Martina McDermott, Martina Mcdermott, Martina S J McDermott, Martina S McDermott, Martina S-J McDermott, Martina S. J. McDermott, Martina S. McDermott

208

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Dublin City University St. Vincent's University Hospital Royal College of Surgeons in Ireland University of South Carolina

About

Martina S.J. McDermott is an author at University of California, Los Angeles specializing in medicine, cell biology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	519
2	Cell Biology	7	7	519
3	Pathology	2	2	61
4	Health Sciences	1	1	307
5	Immunology	1	1	24

Martina S.J. McDermott

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies Martina S.J. McDermott, Alex J. Eustace, Steven Busschots, Frontiers in Oncology Chemoprevention StrategyMetronomic ChemotherapyCancer ChemotherapyMultiple Cell LinesDrug Resistance	2014	307
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Breast Cancer Research	2020	150
CDK8/19 Mediator kinases potentiate induction of transcription by NFκB Mengqian Chen, Jiaxin Liang, Hao Ji, Proceedings of the National Academy of Sciences	2017	134
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer Martina S.J. McDermott, Alexander A. Chumanevich, Chang‐Uk Lim, Oncotarget	2017	128
Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis Eric R. Welin, Aurapat Ngamnithiporn, Max Klatte, Science	2018	119
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo Xiaokai Ding, Amanda C. Sharko, Martina S.J. McDermott, Proceedings of the National Academy of Sciences	2022	50
Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors Sweta Rani, Claire Corcoran, Liam Shiels, Cancer Research Drug TargetBreast OncologyPharmacotherapyCandidate BiomarkerTumor Biology	2014	44
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy Martina S.J. McDermott, Brigid C. Browne, Neil T. Conlon, Molecular Cancer	2014	42
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells Martina S.J. McDermott, Alexandra Canonici, Laura Ivers, International Journal of Oncology Tumor BiologySystems BiologyOncologyHer2 Targeted TherapyBreast Oncology	2017	39
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells Martina S.J. McDermott, Neil T. Conlon, Brigid C. Browne, Cancers Breast OncologyCell DeathLapatinib-induced SenescenceHer2 Targeted TherapiesCancer Biology	2019	39

Page 1